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Abstract
Chronic hepatitis B virus (HBV) infection is a global public health issue. Although the disease cannot be cured
effectively, disease management has been improved over the past decade. The introduction of potent nucleos(t)ide
analogues (NAs) to suppress viral replication represented a giant leap in the control of this disease. It has been
shown that tenofovir treatment, a potent NA, complements current immunoprophylaxis to diminish mother-to-
infant transmission in pregnant women with a high viral load. For patients with chronic HBV infection, quantitative
hepatitis B surface antigen is a useful tool to define inactive carriers and to guide antiviral therapy. Quantification of
HBV mutants is also useful in predicting long-term outcomes more precisely than ever. The next challenge is how
to achieve an HBV cure; although immunotherapy is a promising strategy, the current results from two clinical trials
using therapeutic vaccines to induce HBV-specific immune response in patients with chronic HBV infection are
disappointing. In the coming years, we are expecting to see a combination of therapeutic agents with various
modes of action to complete the mission of HBV elimination.
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Background
Chronic hepatitis B virus (HBV) infection continues to
be a major global public health issue despite the avail-
ability of effective HBV vaccines for over three decades.
Recent data estimated that more than 240 million indi-
viduals worldwide are positive for hepatitis B surface
antigen (HBsAg) [1]. Several viral, host, and environ-
mental factors have been identified in subjects who are
at increased risk of developing liver cirrhosis, hepatic de-
compensation, and hepatocellular carcinoma (HCC) [2].
Although HBV has been discovered for more than half
a century, a cure for chronic hepatitis B (CHB) remains
a challenging task [3]. Currently approved antiviral treat-
ments for CHB include nucleos(t)ide analogues (NAs)
and interferon. NAs effectively suppress HBV replication
to undetectable levels through inhibition of viral reverse
transcriptase. However, rebound of viremia frequently
occurs after discontinuation of NA, primarily because of
the persistence of the active transcriptional template of
HBV covalently closed circular DNA (cccDNA). In con-
trast, interferon is known to have a dual effect – direct
suppression of viral replication and indirect enhance-
ment of host immunity against the virus. Nevertheless,
the overall viral response rate of 30% to interferon is far
from satisfactory. In this minireview, recent advances of
HBV management and strategies to eliminate HBV will
be summarized and discussed.
Management of patients with CHB
Role of quantitative HBsAg in predicting HCC
development and treatment response
The application of qualitative HBsAg in the clinical man-
agement of CHB patients has been increasingly adopted
[4]. It is generally believed that serum HBV DNA level is a
major driver of disease progression in CHB patients [5]. In
particular, patients with serum HBV DNA levels ≥
2000 IU/mL at study entry have an increased risk of devel-
oping HCC over time. In contrast, those with HBV DNA
levels < 2000 IU/mL are usually designated as low viral
load patients. Data from two independent cohorts from
Taiwan consistently showed that serum HBsAg levels of
1000 IU/mL could stratify different HCC risks in patients
with low viral loads [6, 7]. In addition to HCC risks, a
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lower serum HBsAg level (<1000 vs. > 1000 IU/mL) has
also been shown as an indicator of lower risk of viral re-
lapse, hepatitis B e antigen (HBeAg)-negative hepatitis,
and cirrhosis development in CHB patients [8–11]. These
emerging data infer that we may define minimal-risk HBV
carriers by combining low viral load (<2000 IU/mL) and
low HBsAg level (<1000 IU/mL) [11]. Another clinical
usefulness of quantitative HBsAg is to guide physicians re-
garding cessation of antiviral therapy. Serum HBsAg
levels > 20,000 IU/mL at week 24 of treatment are used to
predict non-responders in HBeAg-positive patients receiv-
ing 12-month pegylated interferon therapy [12]. In
addition, quantitative HBsAg may predict who can main-
tain a sustained viral response after stopping NA treat-
ment [13–15]. Although the reported HBsAg cutoff levels
ranged from 10 to 150 IU/mL, the data consistently
showed that the lower the HBsAg level, the lower the risk
of viral and clinical relapse. Further large-scale prospective
studies are needed to define a reliable HBsAg cutoff level
for identification of CHB patients who can cease NA treat-
ment safely.
Role of quantitative viral mutants in predicting different
clinical outcomes
Quantification of HBV mutants has also become a useful
tool for the management of CHB infection. HBV is the
smallest human DNA virus and viral mutants develop
during the course of persistent infection because of the
spontaneous error of viral reverse transcription. Two
common HBV mutants, precore stop codon (G1896A)
and basal core promoter (BCP; A1762T/G1764A) muta-
tions, can respectively abolish and reduce the production
of HBeAg [16]. The presence of these viral mutants has
been shown to be associated with disease progression to
HCC [17, 18]. However, these viral mutants were deter-
mined using qualitative population sequencing, and
therefore the data provided limited information to
correlate with clinical profiles [17, 18]. With advances in
biotechnology, quantification of these viral mutants is
now possible (Table 1). Quantification of precore/BCP
can serve as a predictor of HBeAg seroconversion either
spontaneously or induced by interferon-based treatment
[19, 20]. The percentage of BCP mutants can be used to
predict clinical outcomes such as the development of
liver cirrhosis [21]. Furthermore, the ultimate tool for
viral genome research, next-generation sequencing, has
been recently introduced into HBV research, being able
to determine the minor variant even at the level of 1%.
Recent data using next-generation sequencing to deter-
mine viral variants has been shown to predict HBsAg
loss in HBV carriers receiving 4-year tenofovir (TDF)
treatment, a potent NA [22]. However, these findings
need to be validated by subsequent larger studies. Thus,
quantification of HBV mutants provides viral informa-
tion in greater detail, allowing clinicians to implement
precision medicine in the foreseeable future.
Strategies to eliminate HBV
Combination of TDF and immunoprophylaxis to minimize
mother-to-child transmission (MTCT) of HBV
Interruption of HBV transmission routes is the most ef-
fective way to reduce the global burden of HBV infec-
tion. The combination of hepatitis B immunoglobulin
and hepatitis B vaccine as immunoprophylaxis in new-
borns has been shown to reduce the rate of MTCT from
90 to 10% [23]. However, immunoprophylaxis imple-
mentation has been reported to have a failure rate of
10–30% in infants born to mothers with an HBV DNA
level of more than 200,000 IU/mL [23]. To overcome
the gap, a non-randomized study from Taiwan firstly
showed that MTCT risk was reduced by TDF treatment
in the third trimester of pregnancy in HBeAg-positive
mothers with high viral loads [24]. The results were fur-
ther reinforced by a randomized controlled study in
Table 1 Quantification of HBV variants and its clinical application
Nie et al. [19] Yang et al. [20] Tseng et al. [21] Bayliss et al. [22]
Quantification assay Selective inhibitory polymerase
chain reaction
Pyrosequencing Pyrosequencing Next generation sequencing
Target region PC (G1896A) & BCP
(A1762T/G1764A) mutants








<1% 10% 10% <1%




with a median follow-up




Main finding Levels of PC and BCP
mutants may predict
the time of HBeAg
seroconversion
Quantitative analysis of PC
and BCP mutants can
predict interferon-induced
HBeAg seroconversion
A higher percentage of BCP
mutant is associated with
higher risks of cirrhosis
development
Detectable BCP or PC mutants
are associated with a lower
probability of HBsAg loss during
tenofovir therapy.
Note
PC precore stop codon, BCP basal core promoter, HBeAg hepatitis B e antigen, HBsAg hepatitis B surface antigen
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China [25]. The per-protocol analysis showed that the
transmission rate dropped from 7% in the control group
to 0% in the TDF treatment group at postpartum week
28 (Table 2). Although a longer duration and larger
number of participants are needed to evaluate the safety
profile in infants, a short-term TDF therapy for pregnant
mothers with HBV DNA levels > 200,000 IU/mL does
minimize MTCT risk. Therefore, this will become the
standard of care to prevent HBV transmission in this
unique clinical setting.
The possible mission of functional cure for HBV
HBsAg loss is regarded as a functional cure for HBV and
serves as an ideal treatment endpoint. Nevertheless, it is
rare to achieve the ultimate goal using current treatment
modalities. There are several novel strategies to clear
HBsAg, including killing of HBV-infected hepatocytes via
cytotoxic T cell (CTL)-induced immunotherapy as the
most promising one. Although HBV-specific CTL re-
sponse is vigorous and multi-specific during acute HBV
infection, it is usually weak or even undetectable during
the CHB stage [26]. An ideal immune-therapeutic strategy
should combine profound suppression of viral replication
to prevent uninfected hepatocytes from HBV infection
and restoration of HBV-specific CTL response to clear the
infected hepatocytes. The former goal can be achieved by
existing NA treatment and the later one could be partially
enhanced by therapeutic vaccines [27]. To date, two clin-
ical trials have been performed using different therapeutic
vaccines to treat CHB patients with a similar strategy, yet
the results of both have been disappointing [28, 29]; nei-
ther of the two therapeutic vaccines could clear HBsAg
more effectively compared to the control group. There are
two issues that must be considered. Firstly, HBV-specific
CTL function has been shown to be preserved in children
and young adults, but not in older patients [30]. Since
both studies enrolled older patients, HBV-specific CTL
response may fail to be triggered by therapeutic vaccina-
tions. Second, the immune tolerant effects of the liver
microenvironment must be considered. HBV-specific
CTL response can be induced in peripheral blood, but is
rapidly exhausted after the initiation of cytotoxic effects
against HBV-infected hepatocytes (Fig. 1a,b). Either of the
above issues may have led to the failure of the two clinical
trials. If the failure was caused by the engagement of PD-1
on T cells and PD-L1 on hepatocytes, which leads to the
inhibition of T cell receptor-mediated lymphocyte prolifer-
ation and cytokine secretion, an immune checkpoint in-
hibitor, such as anti-PD1, could be considered as an
addition to the therapeutic vaccine for the amplification of
these effects (Fig. 1c). Indeed, the success of this combin-
ation strategy has been demonstrated in a woodchuck
model [31]. Although the current results of immunother-
apy in CHB treatment are unsatisfactory, it remains the
most attractive method to clear the virus as long as the
appropriate patient population can be selected and opti-
mal study designs can be implemented.
Perspectives
Potent NA treatment has improved the management of
CHB infection over the past decade [32]. Prolonged NA
treatment has halted disease progression and halved the
HCC incidence in CHB patients who have already devel-
oped liver cirrhosis [33–35]. The next challenge is to
achieve functional HBV cure and the development of new
agents with various modes of action is urgently awaited. In
the clinical practice, additional unmet needs should also be
addressed. The first is to identify patients who require
HCC surveillance. Previous studies have indicated that ap-
proximately 25–40% of patients with CHB infection will
develop HCC in their lifetime, and therefore HCC surveil-
lance is indicated [36]. Although prediction of HCC is diffi-
cult, it is possible to identify true inactive HBV carriers
who are at the lowest risk of HCC development by
Table 2 Summary of 2 clinical trials using tenofovir to reduce mother-to-infant transmission on top of standard immunoprophylaxis
Study Chen et al. [24] Pan et al. [25]
Study design Prospective non-randomized control trial Prospective randomized control trial
No. of mother TDF (N = 92), Control (N = 56) TDF (N = 97), Control (N = 100)
Intervention TDF vs. Control TDF vs. Control
Time of intervention 30–32 weeks of gestation 30-32 weeks of gestation
Maternal viral load ≥20,000,000 IU/mL ≥200,000 IU/mL
Maternal HBeAg-positive rate 100% 100%
Mother-to-infant transmission rate TDF (1.54%) vs. Control (10.71%), P = 0.0481* Intention-to-treat analysis: TDF (5%)
vs. Control (18%), P = 0.007**
Per-protocol analysis: TDF (0%)
vs. Control (7%), P = 0.01
Note
TDF tenofovir, HBeAg hepatitis B e antigen
* Defined by HBsAg positivity at 6 months postpartum
** Defined by serum HBV DNA level of more than 20 IU per milliliter (i.e., above the lower limit of detection) or HBsAg positivity at 28 weeks postpartum.
Participants who lost to follow-up or who discontinued treatment were counted as having treatment failure
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combining multiple host, viral, and liver fibrosis markers.
The current criteria to define inactive carriers include nor-
mal ALT level, negative HBeAg, HBV DNA< 2000 IU/mL,
and HBsAg < 1000 IU/mL; their HCC risk is comparable
to that of the normal population [6]. The possibility of fur-
ther reduction of HCC risks by including biomarkers, such
as a liver biomarker indicating early liver fibrosis stage,
along with the current criteria should be explored.
The second issue to be addressed is whether HCC de-
velopment could be prevented by earlier initiation of NA
treatment in CHB patients. Most of the evidence of HCC
risk reduction comes from prolonged NA treatment in pa-
tients with HBV-related liver cirrhosis [33–35]. However,
all studies show that HCC still develops during long-term
NA therapy. This fact may suggest HCC development is
inevitable once advanced liver fibrosis has occurred. Fur-
ther evidence has been provided by the recent finding that
the integration of the HBV genome into the host chromo-
some, which is considered as an oncogenic event, could
be detected at the early stage of chronic infection [37].
Collectively, it is conceivable to achieve an HCC-free era
through early initiation of NA therapy before emergence
of significant fibrosis or massive viral genome integration.
This may be implemented into practice by widening the
therapeutic target of HBV carriers and earlier identifica-
tion using more comprehensive screening. This strategy
may provide an alternative method to eliminate HCC risk
before curing HBV. However, this concept needs to be
proved by clinical studies.
Conclusions
Various measures, including universal hepatitis B vaccin-
ation and interruption of transmission routes, are required
to reach the ultimate goal of global HBV eradication. Po-
tent NA treatment has remarkably improved the preven-
tion of MTCTand management of CHB. We are expecting
to see less disease progression and less HCC development
in CHB patients following initiation of prolonged NA ther-
apy. However, the current armamentarium does not com-
pletely clear HBsAg, and new combination treatment
modalities are needed to achieve a functional HBV cure in
the near future, hopefully by the year 2030 [38].
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PD1 and PD-L1 engagement. c Combining anti-PD1, an immune checkpoint inhibitor, with strategy b may be a solution to cure chronic HBV infection
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